Last $73.74 USD
Change Today +0.09 / 0.12%
Volume 2.0M
As of 8:10 PM 09/16/14 All times are local (Market data is delayed by at least 15 minutes).

intermune inc (ITMN) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/12/14 - $73.79
52 Week Low
02/5/14 - $10.95
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for INTERMUNE INC (ITMN)

intermune inc (ITMN) Related Businessweek News

View More BusinessWeek News

intermune inc (ITMN) Details

InterMune, Inc., a biotechnology company, focuses on the research, development, and commercialization of therapies for pulmonology and orphan fibrotic diseases in North America and Europe. The company develops therapies for the treatment of idiopathic pulmonary fibrosis (IPF), a progressive, irreversible, and fatal lung disease. It markets and sells pirfenidone, an orally active, anti-fibrotic agent that inhibits the synthesis of TGF-beta and TNF-alpha under the Esbriet name for the treatment of adults with mild to moderate IPF in the European Union and Canada. The company’s pirfenidone has also completed three Phase III clinical trials for the treatment of IPF in the United States. The company provides pirfenidone under the Pirespa trade name for the treatment of IPF in Japan and South Korea; and is also approved for the treatment of IPF in China, India, Argentina, and Mexico. Its research programs are focused on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases. The company was formerly known as InterMune Pharmaceuticals, Inc. and changed its name to InterMune, Inc. in April 2001. InterMune, Inc. was founded in 1998 and is headquartered in Brisbane, California.

392 Employees
Last Reported Date: 08/7/14
Founded in 1998

intermune inc (ITMN) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $703.4K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $412.0K
Executive Vice President and Managing Directo...
Total Annual Compensation: $439.5K
Chief Business Officer and Executive Vice Pre...
Total Annual Compensation: $380.0K
Executive Vice President, General Counsel and...
Total Annual Compensation: $196.9K
Compensation as of Fiscal Year 2013.

intermune inc (ITMN) Key Developments

Investor Files Lawsuit Against Takeover of InterMune, Inc

The Shareholders Foundation, Inc. announced that an investor, filed a lawsuit in effort to stop the proposed takeover of InterMune Inc. by Roche for $74.00 per share. On August 24, 2014, Roche and InterMune, Inc. announced they have entered into a merger agreement for Roche to fully acquire InterMune at a price of $74.00 per share in an all-cash transaction. However, the plaintiff claims the offered price is unfair and grossly inadequate because it does not reflect the intrinsic value of InterMune's common stock. The plaintiff says that if the proposed transaction closes, ITMN shareholders will be denied the growth opportunity InterMune has been touting. In addition, the plaintiff alleges that the defendants have also exacerbated their alleged breaches of fiduciary duty by agreeing to lock up the proposed transaction with preclusive deal protection devices, such as a no solicitation, a matching rights, and a $266 million termination fee provision, that preclude other bidders from making successful competing offers for InterMune Inc.

Roche Holding AG, InterMune, Inc. - M&A Call

To consider a definitive merger agreement for Roche to fully acquire InterMune

Investors Reportedly Eyes Stake In InterMune

Sanofi SA-(Sanofi AG) and Roche Holding AG (SWX:ROG) are the bidders to acquire InterMune, Inc. (NasdaqGS:ITMN), people with knowledge of the matter said. Also bidding for InterMune are GlaxoSmithKline plc (LSE:GSK) and Actelion Ltd. (SWX:ATLN), said the people, asking not to be identified because the process is private. Sanofi has so far shown the most interest in a deal, one person said. Goldman Sachs Group Inc. and Centerview Partners LLC are helping InterMune sort through bids for the business, the people said. Representatives for InterMune, Sanofi (SAN), Actelion, Roche, GlaxoSmithKline, and Goldman Sachs declined to comment. Representatives for Centerview couldn’t be reached. Shares of InterMune went up by 14% to $52.06.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ITMN:US $73.74 USD +0.09

ITMN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ARIAD Pharmaceuticals Inc $5.88 USD +0.07
Array BioPharma Inc $3.76 USD +0.01
Medivation Inc $96.91 USD +3.64
Seattle Genetics Inc $41.51 USD +0.69
Spectrum Pharmaceuticals Inc $8.01 USD -0.06
View Industry Companies

Industry Analysis


Industry Average

Valuation ITMN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 65.6x
Price/Book 22.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 64.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INTERMUNE INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at